Cellcept and Humulin n drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cellcept (mycophenolate mofetil) and Humulin n (insulin susp isophane recombinant human). Common drug interactions include cardiac failure congestive among females and blood glucose increased among males.

The phase IV clinical study analyzes what interactions people have when they take Cellcept and Humulin n. It is created by eHealthMe based on reports of 36 people who take the same drugs from the FDA, and is updated regularly.

What is Cellcept?

Cellcept has active ingredients of mycophenolate mofetil. It is often used in systemic lupus erythematosus. eHealthMe is studying from 41,872 Cellcept users. Check the latest studies of Cellcept.

What is Humulin n?

Humulin n has active ingredients of insulin susp isophane recombinant human. It is often used in diabetes. eHealthMe is studying from 9,878 Humulin n users. Check the latest studies of Humulin n.



On Jul, 13, 2026

36 people who take Cellcept and Humulin n together, and have interactions are studied.

Cellcept and Humulin n drug interactions.

What are the common drug interactions of Cellcept and Humulin N, by gender? *:

female:

  1. Cardiac failure congestive
  2. Cellulitis (infection under the skin)
  3. Chest pain
  4. Cystitis bacterial (inflammation of the wall of the bladder by bacteria escherichia coli)
  5. Death
  6. Diabetic nephropathy (diabetic kidney disease)
  7. Diarrhoea
  8. Disease progression
  9. Drug effect decreased
  10. Drug ineffective

male:

  1. Blood glucose increased
  2. Blood glucose decreased
  3. Fluid retention (an abnormal accumulation of fluid in the blood)
  4. Thrombosis (formation of a blood clot inside a blood vessel)
  5. Vision blurred
  6. Anaemia (lack of blood)
  7. Asthenia (weakness)
  8. Catheter site pain
  9. Failure to thrive (inadequate weight gain and physical growth in children)
  10. Lumbar vertebral fracture

What are the common drug interactions of Cellcept and Humulin N, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anogenital warts
  2. Buschke-lowenstein's tumour (genital tumour is a poorly defined)
  3. Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)
  4. Cystitis bacterial (inflammation of the wall of the bladder by bacteria escherichia coli)
  5. Diabetic nephropathy (diabetic kidney disease)
  6. Gangrene (body tissue dies)
  7. Hallucination (an experience involving the perception of something not present)
  8. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  9. Wound infection staphylococcal

40-49:

  1. Mixed connective tissue disease (an autoimmune disease, in which the body's defence system attacks itself)
  2. Nausea (feeling of having an urge to vomit)
  3. Peripheral swelling
  4. Pyrexia (fever)
  5. Renal disorder (kidney disease)
  6. Renal failure (kidney dysfunction)
  7. Rib fracture
  8. Scleroderma (hard skin)
  9. Sinusitis (inflammation of sinus)
  10. Systemic sclerosis (an autoimmune or connective tissue disease. it is characterized by thickening of the skin)

50-59:

  1. Urinary tract infection
  2. Blood glucose increased
  3. Arthralgia (joint pain)
  4. Fatigue (feeling of tiredness)
  5. Headache (pain in head)
  6. Paronychia (infection in the tissues adjacent to a nail on a finger or toe)
  7. Pruritus (severe itching of the skin)
  8. Staphylococcal infection (an infection with staphylococcus bacteria)
  9. Arrhythmia (irregular heartbeat)
  10. Escherichia test positive

60+:

  1. Fall
  2. Interstitial lung disease
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Raynaud's phenomenon (discoloration of the fingers, toes, and occasionally other areas)
  5. Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
  6. Acute respiratory failure
  7. Ankle fracture
  8. Blood alkaline phosphatase increased
  9. Brain contusion (a form of traumatic brain injury)
  10. Cardiac failure congestive

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 4 people, 11.11%
  2. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 3 people, 8.33%
  3. Pain: 3 people, 8.33%
  4. Lipodystrophy Acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired): 3 people, 8.33%
  5. Type 2 Diabetes: 2 people, 5.56%
  6. Nausea (feeling of having an urge to vomit): 2 people, 5.56%
  7. High Blood Pressure: 2 people, 5.56%
  8. Constipation: 2 people, 5.56%
  9. Asthma: 2 people, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Cellcept and Humulin n?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cellcept and Humulin n:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cellcept:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Humulin n:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cellcept and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Humulin n and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil and insulin susp isophane recombinant human (the active ingredients of Cellcept and Humulin n, respectively), and Cellcept and Humulin n (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: